BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B
○
Discoveries/PONATINIB
✓ X-VAULT VERIFIEDEXPLORATORYNOVELTY: MODERATE

PONATINIB

Similarity bridge: ponatinib ↔ vandetanib via ABL1, KIT, FLT3 +7 more candidate

31.0
discovery score
PubMed Studies
—
Novelty
Moderate
Signal
Exploratory
Sealed
May 14, 2026
BiohacksAI Hypothesis

Ponatinib may modulate the Similarity bridge: ponatinib ↔ vandetanib via ABL1, KIT, FLT3 +7 more pathway based on its molecular target profile in the BiohacksAI corpus. This compound shows biological activity against validated targets with limited prior literature coverage, suggesting an understudied mechanism-of-action with potential research value.

Computational hypothesis based on target graph analysis. Not a confirmed mechanism. Independent experimental validation required.

Mechanism Discovery Graph
ABL1KITFLT3KDRFGFR1RETSRCABL2PONATINIB
High-value target (Tier 3)
Research target (Tier 2)
Standard target
Pathway
Knowledge gap (≤5 studies)
Biological Plausibility

The Similarity bridge: ponatinib ↔ vandetanib via ABL1, KIT, FLT3 +7 more pathway is a validated biological target area with established relevance in human disease and health research.

Ponatinib shows target overlap with compounds previously characterized in this pathway within the BiohacksAI corpus of 31,590 graph entities and 1.51M PubMed studies.

Novelty Indicators
Literature coverage
Pending ledger sync
Low coverage = higher novelty potential
Discovery score
31.00
target_count × pathway_diversity / log(studies + 2)
Mechanism area
Similarity bridge: ponatinib ↔ vandetanib via ABL1, KIT, FLT3 +7 more
Primary biological pathway
Novelty rating
Moderate
Derived from score + literature coverage
Research Context
◈
Literature coverage
Detailed data pending ledger sync
◈
X-Vault timestamp
Sealed May 14, 2026 — cryptographic proof of discovery date and corpus version
◈
Corpus scope
BiohacksAI corpus only — not a comprehensive literature or patent database search
◈
Mechanism area
Similarity bridge: ponatinib ↔ vandetanib via ABL1, KIT, FLT3 +7 more — computationally derived, requires experimental confirmation

This section reflects computational signal strength only. All findings require independent expert validation before any research or commercial use.

Suggested Validation Steps
1Similarity bridge: ponatinib ↔ vandetanib via ABL1, KIT, FLT3 +7 more pathway target binding assay
2Dose-response curve (EC50 determination)
3Cellular viability and selectivity panel
4In vitro ADMET profiling

Validation roadmap is algorithmically derived from pathway context. Full experimental protocol available in Priority Signal discovery reports.

Target Relevance
ABL1
High value
KIT
Standard
FLT3
Standard
KDR
Standard
FGFR1
Standard
RET
Standard

Target tier based on BiohacksAI HIGH_VALUE_TARGETS registry.

Discovery Lineage
Generated byBiohacksAI Discovery Engine
Engine versionDISCOVERY_v1.2
Corpus versioncurrent
Graph entities31,590 compounds analyzed
PubMed coverage1.51M studies
Discovery dateMay 14, 2026 at 03:00 AM UTC
X-Vault Evidence SealXVAULT_v1
Discovery IDdisc_T2_ponatinib_vandetanib_c547bb50
Event Hash0bd60c7e8e816848…456ada63
Chain Hashd08056e30fc533bb…2fcbfd2f
Vault Index#2992
Sealed At2026-05-14T03:00:00.774Z
Verify this discovery →↓ Demo PDF (X-Vault sealed)

Demo report — computational hypothesis only. Not validated. For X-Vault verification testing.

Full Discovery ReportLOCKED
🔒
Mechanism hypothesis (expanded)
Detailed molecular mechanism with target confidence scores and binding context
🔒
Complete target mapping
All validated molecular targets with affinity data and evidence levels
🔒
Biological pathway network
Full pathway coverage map with crosstalk and downstream effects
🔒
Graph position + related compounds
Structural neighbors in the BiohacksAI compound graph — potential analogs
🔒
Supporting PMIDs
Curated PubMed references with relevance ranking
🔒
X-Vault sealed PDF
Cryptographically verified 20-30 page discovery report

Interested in this discovery? Contact us for access and licensing details.

Contact us about this discovery →

All discoveries are computational hypothesis candidates — not confirmed mechanisms. Independent experimental validation is required before any research or commercial use. Organiq Sweden AB · BiohacksAI β